Multidrug-Resistant Tuberculosis in Canada: What public health needs to know

In this presentation, we will describe concerns related to global and national multidrug resistant tuberculosis (MDR TB) epidemiology. We will also review key steps in prevention, diagnosis, and treatment. Important challenges faced by Canadian public health systems in responding to MDR TB and solutions to support people who are affected will also be discussed.   

Tuberculosis (TB) Journey in Northern First Nations Communities

NEW* Social Determinants and the TB Journey video.

The TB Journey Map for Northern First Nations Communities is an educational resource for services providers in TB-affected First Nations communities. It visually depicts the key stages in a typical patient journey with emphasis on the different health-care related, social and First Nations determinants of health.

TB Talks Season 2 – A Community Outbreak Story

In partnership with This 4-episode docuseries follows the course of a 2019 TB outbreak in a small, northern First Nations community. The series delivers: in-depth stories of TB survivors and front line workers; educational information on promising strategies for outbreak response; insights into what is needed to end TB in northern First Nations communities. This…

Towards TB Elimination Shared Priorities for TB Program Performance Measurement in Canada – A Proposal for Discussion

This report can be used as a resource to support TB program performance indicator development across programs. Its results should be shared and discussed by public health personnel, federal, provincial and territorial decision‐makers, and others involved in planning and delivering TB programs in Canada. Report Tables Supplementary Tables

Multi-Drug Resistant Tuberculosis – International Resources for Canadian Public Health Personnel

COMMENTARY: Yoav Keynan, MD and NCCID’s Scientific Lead COMMENT According to the WHO 2017 report, in 2016 globally, there were 600,000 new cases of tuberculosis with resistance to rifampicin, the most effective first-line drug, of which 490,000 cases had multidrug-resistant TB (MDR-TB), defined as resistance to rifampicin and isoniazid. Almost half (47%) of these cases…